Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sexual reproduction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    110 result(s) found for: Sexual reproduction. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2012-002047-26 Sponsor Protocol Number: FDC116115 Start Date*: 2012-10-03
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: FDC116115: A prospective study of sexual function in sexually active men treated for BPH
    Medical condition: BPH (Benign prostatic hyperplasia)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    15.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed) NL (Completed) HU (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004055-38 Sponsor Protocol Number: FM41 Start Date*: 2007-05-21
    Sponsor Name:Futura Medical Developments (FMD) [...]
    1. Futura Medical Developments (FMD)
    2. SSL International Plc
    Full Title: A Phase II Clinical Study to Compare the Efficacy and Safety of Three Doses of Topical Glyceryl Trinitrate (GTN) to Placebo in Subjects with Mild and/or Moderate Erectile Dysfunction (ED)
    Medical condition: Mild and/or moderate erectile dysfunction (ED)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061461 Erectile dysfunction LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001031-27 Sponsor Protocol Number: CQ4COV19 Start Date*: 2020-03-14
    Sponsor Name:FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA
    Full Title: Treatment of non-severe confirmed cases of COVID-19 and chemoprophylaxis of their contacts as prevention strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)
    Medical condition: SARS-CoV-2 Respiratory Viral Infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004023-20 Sponsor Protocol Number: MK-3475-992 Start Date*: 2020-02-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Pa...
    Medical condition: Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IE (Completed) DK (Prematurely Ended) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000001-25 Sponsor Protocol Number: OXO-001-201 Start Date*: 2021-08-06
    Sponsor Name:Oxolife S.L.
    Full Title: A phase II, randomised, double-blind, parallel-group, placebo-controlled trial to assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks following fresh single blast...
    Medical condition: Infertility treatment and fertility enhancer in women undergoing assisted reproductive techniques or natural reproduction
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed) ES (Ongoing) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-002806-30 Sponsor Protocol Number: PUL-042-402 Start Date*: 2018-12-14
    Sponsor Name:Pulmotect, Inc.
    Full Title: A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Di...
    Medical condition: GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 0 Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-003124-16 Sponsor Protocol Number: KH176-204 Start Date*: 2021-01-12
    Sponsor Name:Khondrion B.V.
    Full Title: A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease.
    Medical condition: Genetically confirmed mitochondrial disease
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005141-32 Sponsor Protocol Number: MYL-1402O-3001 Start Date*: 2016-07-11
    Sponsor Name:Mylan GmbH
    Full Title: Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous...
    Medical condition: Stage IV unresectable, recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) HR (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004252-38 Sponsor Protocol Number: 207495 Start Date*: 2020-04-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants wit...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2018-001991-39 Sponsor Protocol Number: NIR-DT-301 Start Date*: 2019-07-26
    Sponsor Name:SpringWorks Subsidiary 2, PBC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF).
    Medical condition: Desmoid Tumors/Aggressive Fibromatosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003973-23 Sponsor Protocol Number: 213831 Start Date*: 2021-06-29
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Mole...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) IE (Completed) PL (Trial now transitioned) NL (Trial now transitioned) FI (Completed) FR (Completed) BE (Completed) DE (Completed) IT (Prematurely Ended) ES (Ongoing) HU (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005034-42 Sponsor Protocol Number: MK-7684A-008 Start Date*: 2022-01-31
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezoliz...
    Medical condition: Extensive-stage small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002586-39 Sponsor Protocol Number: MC-TER.2/SSc Start Date*: 2016-08-03
    Sponsor Name:medac GmbH
    Full Title: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapy in Subjects With Diffuse Cutaneous Systemic Sclerosis
    Medical condition: Diffuse cutaneous systemic sclerosis (dcSSc)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001280-24 Sponsor Protocol Number: VE202-002 Start Date*: 2022-07-20
    Sponsor Name:Vedanta Biosciences, Inc.
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis
    Medical condition: Mild-to-moderate ulcerative colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001205-16 Sponsor Protocol Number: 54767414SMM3001 Start Date*: 2017-10-18
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
    Medical condition: Smoldering multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002992-16 Sponsor Protocol Number: EMN17/54767414MMY3014 Start Date*: 2019-01-30
    Sponsor Name:European Myeloma Network (EMN)
    Full Title: A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003185-12 Sponsor Protocol Number: MK-3475-C93 Start Date*: 2022-04-08
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or...
    Medical condition: First-line treatment of participants with dMMR advanced or recurrent EC
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10014747 Endometrial carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) NO (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003377-34 Sponsor Protocol Number: 54767414ALL2005 Start Date*: 2018-07-31
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age With Relapsed/Refractory Precursor B-cell o...
    Medical condition: Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    20.0 100000004864 10066110 T-cell lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002275-18 Sponsor Protocol Number: MS100036-0020 Start Date*: 2019-12-26
    Sponsor Name:Merck KGaA
    Full Title: A multicenter study with an open-label Phase Ib part followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and pharmacokinetics of th...
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002320-27 Sponsor Protocol Number: RPC01-301 Start Date*: 2014-11-21
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) PT (Completed) LV (Completed) SE (Completed) NL (Completed) BG (Completed) PL (Completed) ES (Completed) LT (Completed) HU (Completed) GB (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 15:39:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA